journal article·2020-01-01Open access

Design and construction of a magnetic targeting pro-coagulant protein for embolic therapy of solid tumors

Mingyuan Zou, Peilan Xu, Li Wang, Lanlan Wang, Tingting Li, Cong Liu, Lei Shi, Jun Xie, Wanyun Li, Shengyu Wang, Guoqiu Wu, Fanghong Luo, Ting Wu, Jianghua Yan

Abstract

In this study, we have designed a magnetic targeting pro-coagulant protein (MTPCP) for the embolic therapy of solid tumours. The MTPCP consists of a magnetic carrier and a pro-coagulant protein. The pro-coagulant protein used in this study is the fusion protein tTF-EG3287 which is not pro-coagulant when free in the blood circulation, but presents strong pro-coagulant ability once bound to the Neuropilin-1(NRP-1) that is highly expressed on tumour-associated vascular endothelial cells. And the magnetic carrier is O-Carboxymethyl chitosan-coated iron oxide nanoparticles (OCMC/Fe3O4). In vitro, we assessed the NRP-1 targeting ability of the MTPCP using confocal microscopy and flow cytometry, and evaluated the potential pro-coagulant activity of the MTPCP using the Spectozyme FXa assay. In vivo, the magnetic targeting ability of the MTPCP was detected using a living imaging system. At last, we assessed the anticancer activity of the MTPCP on HepG2 tumour bearing BALB/c nude mice models including subcutaneous transplantation and orthotopic transplantation. HepG2 tumour bearing mice models revealed that after intravenous administration of the MTPCP, thrombosis specifically occurs on tumour-associated blood vessels, and resulting in tumour growth retardation. No apparent side effects, such as thrombosis in other organs or other treatment-related toxicity, were observed during the treatment. Our data showed that the MTPCP may be a promising embolic agent for the embolic therapy of solid tumours.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cancer, Hypoxia, and Metabolism · Angiogenesis and VEGF in Cancer · Lipid metabolism and disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical School of Southeast University

Cancer Research Center, School of Medicine, Xiamen University

Center of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University

Funding

the National Natural Science Foundation of China · Science and Technology Foundation of Fujian Province, China

References (51)

Show source-provided references
1. 10.1055/s-0028-108593010.1055/s-0028-1085930 ↗
2. 10.1007/s00270-006-0062-310.1007/s00270-006-0062-3 ↗
3. 10.1038/nbt.407110.1038/nbt.4071 ↗
4. 10.1006/jmbi.1996.007310.1006/jmbi.1996.0073 ↗
5. Drozdowska J. [Tissue factor in endothelial cells-its structure and function according to the current literature]. Postepy Biochem. 2012;58(3):273–280.
6. 10.1126/science.275.5299.54710.1126/science.275.5299.547 ↗
7. 10.1016/S0021-9258(18)98544-310.1016/S0021-9258(18)98544-3 ↗
8. Hu P, Yan J, Sharifi J, et al. Comparison of three different targeted Tissue Factor fusion proteins for inducing tumor vessel thrombosis[J]. Cancer Res. 2003;63(16):5046–5053.
9. 10.1158/1078-0432.CCR-05-038910.1158/1078-0432.CCR-05-0389 ↗
10. 10.1007/s10456-013-9391-410.1007/s10456-013-9391-4 ↗
11. 10.1016/j.bcp.2018.09.02010.1016/j.bcp.2018.09.020 ↗
12. 10.1080/1061186X.2019.156633710.1080/1061186X.2019.1566337 ↗
13. 10.1074/jbc.M50786020010.1074/jbc.M507860200 ↗
14. 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-910.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9 ↗
15. Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells[J]. Cancer Res. 2001;61(15):5736–5740.
16. 10.1002/cncr.1017710.1002/cncr.10177 ↗
17. 10.1038/onc.2016.48210.1038/onc.2016.482 ↗
18. 10.1074/jbc.M51212120010.1074/jbc.M512121200 ↗
19. 10.1021/am800053810.1021/am8000538 ↗
20. 10.1039/c0nr00821d10.1039/c0nr00821d ↗
21. 10.1109/TMAG.2009.203251810.1109/TMAG.2009.2032518 ↗
22. 10.3390/antibiotics702004610.3390/antibiotics7020046 ↗
23. 10.1016/j.phrs.2017.04.00110.1016/j.phrs.2017.04.001 ↗
24. 10.18632/oncotarget.470910.18632/oncotarget.4709 ↗
25. 10.1016/j.apsusc.2013.05.04110.1016/j.apsusc.2013.05.041 ↗
26. 10.1021/cm034890410.1021/cm0348904 ↗
27. 10.1158/0008-5472.CAN-06-166810.1158/0008-5472.CAN-06-1668 ↗
28. 10.1083/jcb.146.1.23310.1083/jcb.146.1.233 ↗
29. 10.1074/jbc.M70355420010.1074/jbc.M703554200 ↗
30. 10.1016/j.jphotobiol.2009.04.00810.1016/j.jphotobiol.2009.04.008 ↗
31. 10.1016/j.colsurfb.2011.09.03210.1016/j.colsurfb.2011.09.032 ↗
32. 10.1093/clinchem/27.8.142710.1093/clinchem/27.8.1427 ↗
33. 10.1002/(SICI)1097-0215(19960410)66:2<239::AID-IJC17>3.0.CO;2-710.1002/(SICI)1097-0215(19960410)66:2<239::AID-IJC17>3.0.CO;2-7 ↗
34. 10.3748/wjg.v18.i47.708710.3748/wjg.v18.i47.7087 ↗
35. 10.1016/j.jhep.2004.01.01010.1016/j.jhep.2004.01.010 ↗
36. 10.1016/j.apsusc.2015.08.14010.1016/j.apsusc.2015.08.140 ↗
37. 10.1016/j.bej.2008.07.00910.1016/j.bej.2008.07.009 ↗
38. 10.1016/0163-7258(94)90037-X10.1016/0163-7258(94)90037-X ↗
39. 10.1615/critrevoncog.v17.i1.5010.1615/critrevoncog.v17.i1.50 ↗
40. 10.1093/neuonc/nov18010.1093/neuonc/nov180 ↗
41. 10.1016/S0140-6736(15)01088-010.1016/S0140-6736(15)01088-0 ↗
42. 10.1006/jsre.2000.603010.1006/jsre.2000.6030 ↗
43. 10.2217/nnm.09.7310.2217/nnm.09.73 ↗
44. 10.1148/radiol.224101126210.1148/radiol.2241011262 ↗
45. 10.1002/bjs.180082014110.1002/bjs.1800820141 ↗
46. 10.3748/wjg.v13.i21.295210.3748/wjg.v13.i21.2952 ↗
47. 10.1097/00000478-199806000-0000210.1097/00000478-199806000-00002 ↗
48. 10.1634/theoncologist.8-5-42510.1634/theoncologist.8-5-425 ↗
49. 10.1007/s10147-012-0445-110.1007/s10147-012-0445-1 ↗
50. 10.1016/j.ejps.2011.06.01310.1016/j.ejps.2011.06.013 ↗
51. 10.1111/j.1440-1746.2006.04474.x10.1111/j.1440-1746.2006.04474.x ↗